Amgen- Blincyto Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Vs Chemotherapy Alone
安進公司的Blincyto加入多週期治療可以將死亡風險減少58%,顯示出優越的整體存活率,相比單獨接受化療。
Amgen- Blincyto Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Vs Chemotherapy Alone
安進公司的Blincyto加入多週期治療可以將死亡風險減少58%,顯示出優越的整體存活率,相比單獨接受化療。
譯文內容由第三人軟體翻譯。